Multicentre Selective Lymphadenectomy Trial II (MSLT-II): A Phase III Multicentre Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
RATIONALE: Lymph node dissection may remove tumour cells that have spread to nearby lymph nodes in patients with localized melanoma. Sometimes, after surgery, the tumour may not need more treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether complete lymph node dissection is more effective than observation in treating patients with localized melanoma who have undergone sentinel lymphadenectomy. PURPOSE: This randomized phase III trial is studying complete lymph node dissection to see how well it works compared to observation in treating patients with localized melanoma and sentinel node metastasis who have undergone sentinel lymphadenectomy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society